Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
Recruiting
Blueprint Medicines Corporation
Phase 1/Phase 2
2017-03-17
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety,
tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic
activity of pralsetinib (BLU-667) administered orally in patients with medullary thyroid
cancer, RET-altered NSCLC and other RET-altered solid tumors.
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
Recruiting
Hoffmann-La Roche
Phase 1/Phase 2
2017-03-17
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety,
tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic
activity of pralsetinib (BLU-667) administered orally in patients with medullary thyroid
cancer, RET-altered NSCLC and other RET-altered solid tumors.
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Recruiting
Blueprint Medicines Corporation
Phase 3
2020-07-24
This is an international, randomized, open-label, Phase 3 study designed to evaluate whether
the potent and selective RET inhibitor, pralsetinib, improves outcomes when compared to a
platinum chemotherapy-based regimen chosen by the Investigator from a list of standard of
care treatments, as measured primarily by progression free survival (PFS), for participants
with RET fusion-positive metastatic NSCLC who have not previously received systemic
anticancer therapy for metastatic disease. Participants who have centrally confirmed
progressive disease on the control arm have the option to crossover to pralsetinib.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
